At 00:00 on January 18, the first helicobacter pylori self-test product in China, the "Ghost Tube" under Nuohui Health-B (06606.HK), was simultaneously launched on the six major e-commerce platforms of Jingdong Health, iKang, Meituan Medicine, Tmall, Ping An Health and Lezhuan. According to the official data of Nuohui Health, the sales volume of The Ghost Tube exceeded 10,000 pieces on the day of its debut, and the sales volume exceeded 220,000.
Affected by this, on January 18, Nuohui Health once rose by 22.06% after the opening, but since then it has continued to decline, closing at HK$28.00 per share, a slight decline of 0.36%. On January 19, Nuohui Health opened low and went high, closing at HK$29.05 per share, up 3.75%, with a total market value of HK$12.484 billion.
Red Star Capital Bureau noted that on January 6, Nuohui Health announced that The Ghost Tube was approved. Affected by the above news, the company's stock price rose by more than 40% on January 7, and by the close of trading on January 19, the cumulative increase of more than 50% in 9 trading days.
Founded in 2015, Nuohui Health focuses on home early screening for high-incidence cancers, and was successfully listed on the Hong Kong stock market on February 18, 2021. In the first half of 2021, the company achieved operating income of 439 million yuan and a net loss of 2.891 billion yuan.
On January 18, UBS released a research report saying that to maintain the "buy" rating of Nuohui Health, the State Food and Drug Administration recently approved the registration of Nuohui Health's product "Yuyu Tube", and the bank raised its target price from HK$48 to HK$52. The company expects total revenue to be between RMB205 million and RMB217 million last year, up 190.8% year-on-year to 207.8%.
According to the data, the ghost tube adopts the integrated design of sampling and detection "pregnancy test stick", the user operation is simple, painless and non-invasive, and the results can be read in 10 minutes. On January 6, "Ghost Tube" was approved by the State Drug Administration (NMPA) for the registration of three types of medical devices, which is the first Helicobacter pylori testing product approved by the State Food and Drug Administration for "consumer self-testing" in China.
With topics such as #Don't be fooled by anti-ghost toothpaste ##More than 60% of families infected with Pylori #have successively appeared on social platforms, Helicobacter pylori has become the first hot concept in early 2022, and related concept stocks have generally ushered in a sharp rise.
According to the incomplete statistics of Red Star Capital Bureau, there are currently 38 A-share Helicobacter pylori concept stocks, including Yuyue Medical (002223. SZ), Daan Gene (002030. SZ), Wanfu Bio (300482. SZ), Azure Bio (603739. SH) and other popular companies.
Red Star News reporter Wu Danruo intern Ao Yulian
Edited by Yu Dongmei
(Download Red Star News, there are prizes for the newspaper!) ）
